<DOC>
	<DOC>NCT00489606</DOC>
	<brief_summary>To assess the pharamcodynamic effects of coadministrated SK3530(PDE5 inhibitor) and tamsulosin, phase I study in healthy volunteers was designed.</brief_summary>
	<brief_title>Phase I Study to Investigate the Drug Interaction After Oral Administration of Tamsulosin and SK3530</brief_title>
	<detailed_description>During each of the two periods of a randomized, double-blind, placebo-controlled, crossover study, 16 healthy men received tamsulosin 0.2 mg daily for 7 days and either a single 100 mg of SK3530 or placebo on day7. The blood pressure and heart rate were monitored before and for 24 hours after SK3530 or placebo.</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>ages 20 to 50 body weight of IBMÂ±20% cardiovascular disease colorblindness or weakness hypotension, hypertension, orthostatic hypertension abmormal QTc (&gt;430 ms)</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>SK3530</keyword>
	<keyword>tamsulosin</keyword>
	<keyword>hemodynamic interaction</keyword>
	<keyword>safety</keyword>
</DOC>